SCHEMBL25822839

SCHEMBL25822839

CC(CCCN)NCCC(=O)OCCCCCOC(=O)CCN(CCCCO)CCC(=O)C(C)OCCCCCOC(=O)CCNC(C)CCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25820610 0.92 ACHE (0.33)
SCHEMBL25822328 0.90
SCHEMBL25820450 0.90 ACHE (0.32)
SCHEMBL25822259 0.85
SCHEMBL21981176 0.82 CYP4F2 (0.31)
SCHEMBL25820461 0.82 HTR2C (0.31)
SCHEMBL25822772 0.81 ACHE (0.31)
SCHEMBL17532406 0.78 ACHE (0.32)
SCHEMBL25822261 0.75 PAOX (0.32)
SCHEMBL20892164 0.72 DNM1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-11 US disclosed